JAK2 and myeloproliferative neoplasm: As it is not possible to clearly delineate the mechanisms of action of ruxolitinib in a clinical setting, we generated a JAK2-V617F MPN mouse model, expressing a JAK2-V617F variant, which is not blocked by ruxolitinib.